Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Licenses RNAi Technology from Stanford University

NEW YORK, Oct. 16 (GenomeWeb News) - Benitec has obtained an exclusive license to use StanfordUniversity's Minicircle DNA technology, the company said last week.

 

Terms of the agreement allow Benitec to use the technology "for all RNAi therapeutic uses, with sub-licensing rights."

 

Minicircles was developed by Mark Kay, professor of pediatrics and genetics at Stanford, and a consultant to Benitec. It enables gene expression "up to 500 times greater" than with traditional plasmid DNA, according to Benitec.

 

"This license advances Benitec's ability to build effective RNAi therapeutics for our in-house disease programs and supports our pathfinder approach to the overall development of RNAi therapeutics," the company said in a statement. "We will ... continue to identify in-licensing opportunities for Benitec in delivery methods and clinical targets from other leading centers of innovation in both the United Statesand abroad."

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.